In a latest development, as per sources, the All India Institute of Medical Sciences (AIIMS) in Delhi from Monday (June 7) will start screening for the clinical trials of the homegrown anti-Covid vaccine, Covaxin, on children, says a report. This comes days after AIIMS Patna started the trials on children.
As per experts, a possible third wave can bring as much devastation as the second wave of the pandemic if enough people are not vaccinated against the virus, and that children could be its prime target.
As of now, Covaxin, Covishield and Sputnik V - have not been approved for use on children.
Dr VK Paul, NITI Aayog member, had said last month that the phase 2 - 3 trials will be conducted on children aged between two and 18. On May 13, the centre gave its clearance to the clinical trials on children.
The trial will be conducted on 525 healthy volunteers across different sites across the country and the vaccine will be given by intramuscular route in two doses at day 0 (the first day) and day 28, according to the Health Ministry.
Talking about countries other than India, the United States and Canada have authorised Pfizer-BioNTech's vaccine for use in some age groups of children. China has also approved the emergency use of CoronaVac, a COVID-19 vaccine manufactured by Chinese firm Sinovac, for children aged between 3 and 17 years. Most countries, however, are not inoculating children against the virus.